Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice

Montero-Pérez-Barquero, Manuel ; Escobar-Cervantes, Carlos ; Arévalo-Lorido, José Carlos ; Conde-Martel, Alicia ; Salamanca-Bautista, Prado ; Manzano-Espinosa, Luis ; Formiga, Francesc ; Díez-Manglano, Jesús (Universidad de Zaragoza) ; Cepeda, José María ; González-Franco, Alvaro ; Casado-Cerrada, Jesús

Resumen: Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This multicenter cohort study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were estimated based on results from the DAPA-HF trial. Results: A total of 1595 patients were enrolled, of whom 1199 (75.2%) were eligible for dapagliflozin. Within 1 year after discharge, 21.6% of patients eligible for dapagliflozin were rehospitalized for HF and 20.5% died. Full implementation of dapagliflozin led to an absolute risk reduction of 3.5% for mortality (number needed to treat = 28) and 6.5% (number needed to treat = 15) for HF readmission. Conclusion: Treatment with dapagliflozin in clinical practice may markedly reduce mortality and readmissions for HF.

Idioma: Inglés

DOI: 10.2217/fca-2023-0016

Año: 2023

Publicado en: Future cardiology 19, 6 (2023), 343-351
ISSN: 1479-6678

Factor impacto CITESCORE: 2.8 - Cardiology and Cardiovascular Medicine (Q3) - Molecular Medicine (Q4)

Factor impacto SCIMAGO: 0.412 - Cardiology and Cardiovascular Medicine (Q3) - Molecular Medicine (Q4)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)